Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat COPD (EU)

August 27, 2008
False economy by companies
By a GLG Expert Contributor
Analysis of: Healthways' Guidance Not So Healthy (www.forbes.com)
Healthways is currently struggling, but hopfully this will only be a temporary local difficulty. In the long run Healthways provides a good service
August 18, 2008
Not too surprising a result
By a GLG Expert Contributor
Analysis of: Heart Stents No Better Than Drugs for Chest Pain Over Time (www.bloomberg.com)
You can only open up an artery so far. Whether you achieve this with drugs, or a mechanical device doesn't seem to matter as long as the blood gets flowing again.
July 9, 2008
New Use for old drugs is something good-and called clinical research.
By a GLG Expert Contributor
Analysis of: One drug, many uses. Good idea? (www.indystar.com)
This article implicates that, while new uses for old drugs are terrifically attractive for drug companies this somehow lessens the drive for them to find new original substances. Of course it is nice to get a new market without paying USD 500 000 000 which is the going rate for a new drug through all...
January 14, 2008
Good but not that much better
By a GLG Expert Contributor
Analysis of: New Inhalation Device With Aclidinium Bromide May Offer Advantages To COPD Patients (www.medicalnewstoday.com)
This is a good inhaler but there is no current evidence the drug is signifcantly better than spiriva.
July 26, 2007
Long term weight loss measured in 24 weeks?
By a GLG Expert Contributor
Analysis of: OREXIGEN(TM) Therapeutics Reports Top-line 24 Week Results for Phase IIb Trial of EMPATIC(TM) to Treat Obesity (www.pipelinereview.com)
New drugs need 2 year data!
June 22, 2007
Encouraging news for a novel theraputic approach
By a GLG Expert Contributor
Analysis of: Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan (www.pipelinereview.com)
This is exciting news about the improvement in patient outcomes. it is unfortunate that they decdied to end the trial early however as with  just 41 patients in the trial - any adverse events that the treatment might cause may arise during wider usage.
November 3, 2006
beware Biowa- anti-Il-5 doesnt work in humans!
By a GLG Expert Contributor
Analysis of: BioWa, Inc. Begins Phase 1 Clinical Trial in Asthma (www.pipelinereview.com)
Recent renewed interest in a failed anti-cytokine approach for asthma.

Page : 11 to 7 of 7

Analytics


Generated at 2009-01-07T19:00:58.307